South Korea Organoids Market Size, Share, and COVID-19 Impact Analysis, By Type (Liver, Kidney, Pancreas, Intestine, and Others), By Application (Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, and Others), and South Korea Organoids Market Insights, Industry Trend, Forecasts to 2035

South Korea Organoids Market Insights Forecasts to 2035

• The South Korea Organoids Market Size was Estimated at USD 34.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 10.54% from 2025 to 2035
• The South Korea Organoids Market Size is Expected to Reach USD 104.2 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the South Korea Organoids Market Size is Anticipated to Reach USD 104.2 Million by 2035, Growing at a CAGR of 10.54% from 2025 to 2035. Growing biotechnology investment, the need for personalized medicine, and the desire for moral substitutes for animal testing are driving the expansion of the South Korean organoids market.

Market Overview

The South Korea organoids market refers to the industry devoted to the creation, marketing, and use of organoids tiny, three-dimensional structures derived from stem cells that replicate the composition and functionality of human organs is known as the South Korean organoids market. Additionally, in South Korea, the growing popularity of personalized medicine is primarily responsible for the demand for organoids in disease modeling and drug development. According to a report, demand for individualized healthcare solutions is predicted to rise by 10% annually, indicating that the personalized medicine market in Asia, including South Korea, will expand quickly. Organizations such as the Korea National Institute of Health, which are encouraging research on the use of organoids to customize treatment regimens, are supporting this surge. The use of organoid technologies improves knowledge of how each patient reacts to treatments, which fuels the expansion of the South Korean organoids market. Furthermore, this type of cooperation aims to accelerate the development and commercialization of organoid technologies. In keeping with the South Korean government's ambitions to become the world's leading biotechnology company, the growing need for 3D cell culture systems also supports the growth of organoid research in fields such as neurobiology, regenerative medicine, cancer, and others.

Report Coverage

This research report categorizes the market for the South Korea organoids market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea organoids market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea organoids market.

Driving Factors

Organoid markets are expanding in South Korea as a result of increased demand for personalized biomedicine and biomedical technological advancements. The government's significant investment in biotechnology, frequently coupled with subsidies and supportive laws that encourage more R&D in the area, is the main driver of the market. Organoids that can be used in drug testing and culturing for customized therapies are presently being developed by South Korean institutions, which could aid in the creation of novel clinical treatments and innovations. Collaboration between universities and biopharma companies, as well as other research-focused organizations, has significantly increased recently.

Restraining Factors

The market for organoids in South Korea lacks standardization, which leads to variations in tissue sourcing, culture techniques, and quality standards, making reproducibility challenging. This compromises clinical application dependability and postpones regulatory approvals, particularly in high-stakes pharmaceutical and personalized medicine applications.

Market Segmentation

The South Korea organoids market share is classified into type and application.

• The liver segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea organoids market is segmented by type into liver, kidney, pancreas, intestine, and others. Among these, the liver segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Liver derived organoids are a major area of interest because of their potential to improve therapeutic development through their use in toxicology evaluations and drug metabolism research.

• The drug testing segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea organoids market is segmented by application into drug testing, developmental biology, personalized medicine, regenerative medicine, and others. Among these, the drug testing segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Drug testing is at the forefront because organoids allow scientists to model how people react to medications, greatly improving the effectiveness and security of drug development procedures.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea organoids market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Samsung Medical Center
• Seoul National University Hospital
• Korea Institute of Science and Technology (KIST)
• ToolGen Inc.
• Others

Recent Developments:

• In June 2025, Samsung Biologics, a leading contract development and manufacturing organization (CDMO), had announced the launch of Samsung Organoids, a drug screening service utilizing organoid technology. This service enabled clients to screen drug candidates more effectively by leveraging organoids’ high patient similarity (up to 85%) and cost-effectiveness compared to traditional testing methods.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Organoids Market based on the below-mentioned segments:

South Korea Organoids Market, By Type

• Liver
• Kidney
• Pancreas
• Intestine
• Others

South Korea Organoids Market, By Application

• Drug Testing
• Developmental Biology
• Personalized Medicine
• Regenerative Medicine
• Others